IB2-IVA 子宮頸がんまたは膣がん患者の治療における化学療法および放射線療法によるトリアピン
局所進行子宮頸がん(LACC)および膣がんに対する同時化学放射線療法と組み合わせた経口トリアピンの第I相用量漸増バイオアベイラビリティ研究
This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer. Triapine may stop the growth of cancer cells by blocking an enzyme needed for cell growth. Cisplatin is a drug used in chemotherapy that kills cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Adding triapine to standard treatment with cisplatin and radiation therapy may kill more cancer cells.
調査の概要
状態
条件
介入・治療
- 薬:Cisplatin
- 手順:Magnetic Resonance Imaging
- 他の:Pharmacological Study
- 手順:Biospecimen Collection
- 放射線:Intensity-Modulated Radiation Therapy
- 手順:Computed Tomography
- 手順:Positron Emission Tomography
- 放射線:Brachytherapy
- 放射線:External Beam Radiation Therapy
- 他の:Fludeoxyglucose F-18
- 放射線:High-Dose Rate Brachytherapy
- 薬:Triapine
詳細な説明
PRIMARY OBJECTIVES:
I. To determine the maximum tolerable dose (MTD) and recommended phase II dose (RP2D) of oral triapine when used in combination with cisplatin plus radiation therapy.
II. To determine the oral bioavailability of triapine. III. To describe the pharmacokinetics (PK) of oral and intravenous triapine.
SECONDARY OBJECTIVES:
I. To determine whether the metabolic complete response (mCR) rate of oral triapine in combination with cisplatin chemoradiation using fludeoxyglucose F 18 (18F-FDG)-positron emission tomography (PET)/computed tomography (CT) at post-therapy (3-month) is at least 70%.
II. To determine clinical overall response rate, progression-free survival, and overall survival.
III. To determine the correlation of methemoglobin proportion (%) and triapine pharmacokinetic exposure.
EXPLORATORY OBJECTIVE:
I. To determine whether active human immunodeficiency virus (HIV) antiretroviral therapy impacts the antitumor activity of triapine.
OUTLINE: This is a dose-escalation study of triapine.
Patients undergo pelvic external beam radiation therapy (EBRT) or intensity modulated radiation therapy (IMRT) 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of low dose rate (LDR) brachytherapy in week 6 or 5 fractions of high dose rate (HDR) brachytherapy at week 4 or 5. Patients also receive triapine intravenously (IV) over 120 minutes on day 1 and orally (PO) on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo magnetic resonance imaging (MRI) and FDG-PET/CT during follow-up.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- University of Alabama at Birmingham Cancer Center
-
-
California
-
Los Angeles、California、アメリカ、90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles、California、アメリカ、90033
- Los Angeles General Medical Center
-
Pasadena、California、アメリカ、91105
- Keck Medical Center of USC Pasadena
-
-
Kansas
-
Fairway、Kansas、アメリカ、66205
- University of Kansas Clinical Research Center
-
Kansas City、Kansas、アメリカ、66160
- University of Kansas Cancer Center
-
Overland Park、Kansas、アメリカ、66211
- University of Kansas Hospital-Indian Creek Campus
-
Westwood、Kansas、アメリカ、66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- University of Kentucky/Markey Cancer Center
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan Rogel Cancer Center
-
Detroit、Michigan、アメリカ、48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills、Michigan、アメリカ、48334
- Weisberg Cancer Treatment Center
-
-
New Jersey
-
New Brunswick、New Jersey、アメリカ、08903
- Rutgers Cancer Institute of New Jersey
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15232
- UPMC Hillman Cancer Center
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- University of Virginia Cancer Center
-
Richmond、Virginia、アメリカ、23298
- VCU Massey Comprehensive Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patient has a new, untreated histologic diagnosis of stage IB2 (> 5 cm), II, IIIB, IIIC or IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix or stage II-IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the vagina not amenable to curative surgical resection alone; the presence or absence of lymph node metastasis will be based on pre-therapy 18F-FDG PET/CT; the patient must be able to tolerate imaging requirements of an 18F-FDG PET/CT scan
-
Age >= 18 years old
-
Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
-
Life expectancy greater than 6 months
-
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
-
Platelets >= 100 x 10^9/L
-
Hemoglobin (Hgb) >= 10.0 g/dL (blood transfusions to reach this amount are allowed)
-
Serum creatinine =< 1.5 mg/dL to receive weekly cisplatin
- If serum creatinine is between 1.5 and 1.9 mg/dL, patients are eligible for cisplatin if the estimated creatinine clearance (CCr) is > 30 ml/min (for the purpose of estimating the CCr, the formula of Cockcroft and Gault for females should be used)
-
Total serum bilirubin =< 1.5 x upper limit of normal (ULN) (in patients with known Gilbert syndrome, a total bilirubin =< 3.0 x ULN, with direct bilirubin =< 1.5 x ULN)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
-
Able to take oral medication
-
Not pregnant and not breastfeeding; the effects of triapine on the developing human fetus are unknown; for this reason as well as because heterocyclic carboxaldehydethiosemicarbazones and radiation are known to be teratogenic, women of child-bearing potential and men must agree to use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; patient must have documented negative urine pregnancy test must be resulted within 7 days before initiating protocol therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with triapine, breastfeeding should be discontinued if the mother is treated with triapine; these potential risks may also apply to other agents used in this study
-
For HIV and hepatitis B/C (HEPB/C):
- HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for the dose escalation portion of this trial; for those patients who are enrolled in the HIV positive (+) expansion cohort, they must be HIV infected and be on retroviral therapy with an undetectable viral load within 6 months of enrollment
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured; for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Able to understand and willingness to sign a written informed consent document
Exclusion Criteria:
- Patient has had a prior invasive malignancy diagnosed within the last three years (except [1] non-melanoma skin cancer or [2] prior in situ carcinoma of the cervix)
- Patients are excluded if they have received prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physician
- Patients receiving any other investigational agents
- Patients with known glucose-6-phosphate dehydrogenase deficiency (G6PD) are excluded due to an inability to administer the antidote for methemoglobinemia, methylene blue; pre-registration testing for G6PD is at the investigator's discretion and is not required for study enrollment
- Patients who are taking any medication associated with methemoglobinemia; medication must be discontinued and must have a washout period of 4 halflives or 4 weeks, whichever is shorter
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatin
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; known inadequately controlled hypertension; significant pulmonary disease including dyspnea at rest, patients requiring supplemental oxygen, or poor pulmonary reserve; or psychiatric illness/social situations that would limit compliance with study requirements
- Patients with uncontrolled diabetes mellitus (fasting blood glucose controlled by medication, =< 200 mg/dL allowed)
- Patients who have had a hysterectomy or are planning to have an adjuvant hysterectomy following radiation as part of their cervical cancer treatment are ineligible
- Patients scheduled to be treated with adjuvant consolidation chemotherapy at the conclusion of their standard chemoradiation
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment (triapine, chemoradiation)
Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up. |
Given IV
他の名前:
Undergo MRI
他の名前:
Correlative studies Undergo collection of blood samples
他の名前:
Undergo IMRT
他の名前:
Undergo FDG-PET/CT
他の名前:
Undergo FDG-PET/CT
他の名前:
Undergo LDR brachytherapy
他の名前:
Undergo pelvic EBRT
他の名前:
Undergo FDG-PET/CT
他の名前:
Undergo HDR brachytherapy
他の名前:
Given IV and PO
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
除去半減期 (t 1/2)
時間枠:投与後24時間以内
|
投与後24時間以内
|
|
|
Maximum Tolerated Dose (MTD)
時間枠:Up to 5 weeks
|
The MTD was determined following a standard 3+3 design is as follows: Escalation at 0/3 DLTs, dose-reduction if >1/3 DLT, and expansion to 6 if 1/3 DLTs. DLT is defined as the severe toxicity event that leads to the termination of the treatment as defined in section 5.5. The highest dose level where <2/6 DLTs are observed will be declared MTD |
Up to 5 weeks
|
|
Number of Patients Who Experienced a DLT
時間枠:Up to 5 weeks
|
Number of patients that experienced a DLT, evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. DLTs are defined as the following adverse events if considered at least "possibly related" to a component of the study therapy and which occur from the start of treatment until completion of EBRT, prior to initiation of brachytherapy (i.e. the first 5 weeks if no treatments are missed): Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 3 toxicity not resolved with maximal intervention to Grade 0-2 over 7 days (except alopecia and fatigue); Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 4 toxicity; Any other non-hematologic toxicity ≥Grade 3; Any hematologic toxicity of ≥ Grade 4; Grade ≥3 dyspnea; Inability to deliver at least 20 of the scheduled 25 administrations of triapine at the planned dose, allowing for 2 weeks to make up missed radiation days. Inability to deliver |
Up to 5 weeks
|
|
Bioavailability of Triapine
時間枠:Up to 2 weeks
|
The oral bioavailability of the oral form of the triapine will be measured as a numeric value using mass spectrophotometry. |
Up to 2 weeks
|
|
Cmax
時間枠:Up to 24 hours after dosing
|
Maximum concentration |
Up to 24 hours after dosing
|
|
Tmax
時間枠:Up to 24 hours after dosing
|
Time to maximum concentration, |
Up to 24 hours after dosing
|
|
AUC
時間枠:Up to 24 hours after dosing
|
Area Under the Concentration-Time Curve (AUC 0-last) |
Up to 24 hours after dosing
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fludeoxyglucose F18-Positron Emission Tomography Computed Tomography Metabolic Complete Response (mCR) Rate
時間枠:At 3 months post-treatment
|
The mCR rate at recommended phase 2 dose, defined as a metabolic complete response on PET/CT will be defined as greater than -66% reduction in tumor FDG uptake at sites of abnormal tumor FDG uptake noted on pre-treatment FDG-PET study (considering normal cardiac or liver blood pool). |
At 3 months post-treatment
|
|
Clinical Overall Response Rate
時間枠:3 months post-treatment
|
Clinical response at the recommended phase 2 dose per RECIST v1.1 Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
3 months post-treatment
|
|
Progression Free Survival (PFS)
時間枠:Up to 4 years and 2 months from start of treatment
|
Median number of months that patients survive without disease progression from end of treatment. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 4 years and 2 months from start of treatment
|
|
Overall Survival (OS)
時間枠:Up to 4 years and 2 months from start of treatment
|
Median number of months that patients remain alive after end of treatment. |
Up to 4 years and 2 months from start of treatment
|
協力者と研究者
捜査官
- 主任研究者:Sarah E Taylor、University of Pittsburgh Cancer Institute LAO
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 泌尿生殖器腫瘍
- 部位別新生物
- 新生物
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 子宮の病気
- 生殖器疾患、女性
- 性器腫瘍、女性
- 子宮頸部疾患
- 子宮腫瘍
- 子宮頸部腫瘍
- 調査手法
- 治療
- 臨床検査技術
- 診断技術と手順
- 診断
- 炭水化物
- 物理現象
- 無機化学物質
- 塩素化合物
- 窒素化合物
- 要素
- 金属
- 組織
- ヘルスケアの経済学と組織
- 化学技術、分析
- スペクトル分析
- 金属、重い
- プラチナ化合物
- 放射線療法
- デオキシグルコース
- デオキシ糖
- 遷移要素
- 放射線療法、コンフォーマル
- 放射線療法、コンピューター支援
- フルオロデオキシグルコース F18
- シスプラチン
- クエン酸1,2-ジアミノシクロヘキサン白金II
- 放射線
- トピックとしての議会
- 標本処理
- 磁気共鳴分光法
- 白金
- 放射線療法、強度変調
- 黒球療法
- 3-アミノピリジン-2-カルボキシアルデヒドチオ科バゾン
その他の研究ID番号
- NCI-2015-01907
- NCI-2015-01907 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- HCC 15-157
- UPCI 15-157
- 15-157
- 9892 (その他の識別子:CTEP)
- UM1CA186690 (米国 NIH グラント/契約)
- 9892 (その他の識別子:UPMC Hillman Cancer Center LAO)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。